BioSante Pharmaceuticals to Present at the Bio Investor Forum
LINCOLNSHIRE, Illinois (October 22, 2009) – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, its president and CEO will present an overview of the company and its recently completed acquisition of Cell Genesys, as well as give a LibiGel® (testosterone gel) update at the Bio Investor Forum to be held on October 28-29, 2009 at the Palace Hotel in San Francisco, California. Mr. Simes will present on October 29 at 1:00 pm local time.
A live audio webcast of BioSante’s presentation at the conference may be accessed at BIO Investor website. A replay will be available at the same link.
About the Bio Investor Forum
The Bio Investor Forum, sponsored by the Biotechnology Industry Organization (BIO), is a national investor forum to explore investment trends and opportunities in life sciences, with a focus on public and venture-stage growth companies as well as those poised to join the growth “watch list” in 2010. The forum is attended by public and private equity investors, research analysts, investment bankers and industry executives focused on investment and business development opportunities in the life sciences.
BIO represents more than 1.200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. BIO also produces the annual BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading innovator and partnering meetings held around the world.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante’s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S.
Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. Under BioSante’s license agreement with Antares Pharma, BioSante is required to pay Antares a portion of the royalties, license and milestone payments received for products covered by that agreement. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional information is available online at: biosantepharma.cdmail.biz.
For more information please contact:
Harris D. McKinney, Inc.